EA201200253A1 - Композиция для лечения муковисцидоза - Google Patents

Композиция для лечения муковисцидоза

Info

Publication number
EA201200253A1
EA201200253A1 EA201200253A EA201200253A EA201200253A1 EA 201200253 A1 EA201200253 A1 EA 201200253A1 EA 201200253 A EA201200253 A EA 201200253A EA 201200253 A EA201200253 A EA 201200253A EA 201200253 A1 EA201200253 A1 EA 201200253A1
Authority
EA
Eurasian Patent Office
Prior art keywords
prostacyclin
treatment
mucoviscidosis
composition
cystic fibrosis
Prior art date
Application number
EA201200253A
Other languages
English (en)
Other versions
EA023720B1 (ru
Inventor
Михаель Фрайсмут
Ксавер Кёниг
Кристина Глёкель
Original Assignee
Сифарм Сарл
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Сифарм Сарл filed Critical Сифарм Сарл
Publication of EA201200253A1 publication Critical patent/EA201200253A1/ru
Publication of EA023720B1 publication Critical patent/EA023720B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5578—Eicosanoids, e.g. leukotrienes or prostaglandins having a pentalene ring system, e.g. carbacyclin, iloprost
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/558—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes
    • A61K31/5585—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes having five-membered rings containing oxygen as the only ring hetero atom, e.g. prostacyclin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Reproductive Health (AREA)
  • Otolaryngology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

В настоящем изобретении предлагаются композиции, содержащие простациклин или аналог простоциклина или его фармакологически приемлемую соль для применения при профилактике или при лечении муковисцидоза. В изобретении также предлагается применение набора, содержащего простациклин или аналог простациклина для лечения или для профилактики состояния, связанного с муковисцидозом у пациента.
EA201200253A 2009-08-07 2010-08-05 Композиция для лечения муковисцидоза EA023720B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09167491 2009-08-07
PCT/EP2010/061428 WO2011015630A1 (en) 2009-08-07 2010-08-05 Composition for the treatment of cystic fibrosis

Publications (2)

Publication Number Publication Date
EA201200253A1 true EA201200253A1 (ru) 2012-07-30
EA023720B1 EA023720B1 (ru) 2016-07-29

Family

ID=41382119

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201200253A EA023720B1 (ru) 2009-08-07 2010-08-05 Композиция для лечения муковисцидоза

Country Status (26)

Country Link
US (2) US20120184622A1 (ru)
EP (1) EP2461812B1 (ru)
JP (1) JP5877787B2 (ru)
KR (1) KR101729800B1 (ru)
CN (1) CN102548559B (ru)
AU (1) AU2010280684B2 (ru)
BR (1) BR112012002578B8 (ru)
CA (1) CA2770066C (ru)
CL (1) CL2012000319A1 (ru)
CY (1) CY1114983T1 (ru)
DK (1) DK2461812T3 (ru)
EA (1) EA023720B1 (ru)
ES (1) ES2451790T3 (ru)
GT (1) GT201200038A (ru)
HK (1) HK1165293A1 (ru)
HN (1) HN2012000297A (ru)
HR (1) HRP20140277T1 (ru)
IL (1) IL217899B (ru)
PL (1) PL2461812T3 (ru)
PT (1) PT2461812E (ru)
RS (1) RS53234B (ru)
SG (1) SG178315A1 (ru)
SI (1) SI2461812T1 (ru)
SM (1) SMT201400057B (ru)
WO (1) WO2011015630A1 (ru)
ZA (1) ZA201200790B (ru)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20180036807A (ko) 2009-06-12 2018-04-09 맨카인드 코포레이션 한정된 비표면적을 갖는 디케토피페라진 마이크로입자
DK2663313T3 (en) * 2011-01-13 2018-11-26 Scipharm S A R L PROCEDURE FOR IMPROVING ENGRAFTMENT OF HEMATOPOIETIC STEM CELLS
LT2672957T (lt) 2011-02-07 2017-02-10 Scipharm Sarl Naujoji kompozicija, skirta cistinės fibrozės gydymui
US9505737B2 (en) 2013-01-11 2016-11-29 Corsair Pharma, Inc. Treprostinil derivative compounds and methods of using same
ES2927844T3 (es) 2013-01-11 2022-11-11 Corsair Pharma Inc Profármacos de treprostinil
CA2906817C (en) 2013-03-15 2022-01-18 Mannkind Corporation Microcrystalline diketopiperazine compositions and methods
MX2016000739A (es) 2013-07-18 2017-04-06 Mannkind Corp Composiciones farmacéuticas en polvo seco estables al calor y métodos.
WO2015061720A2 (en) 2013-10-25 2015-04-30 Insmed Incorporated Prostacyclin compounds, compositions and methods of use thereof
ES2873873T3 (es) 2014-11-18 2021-11-04 Insmed Inc Métodos de fabricación de treprostinilo y profármacos derivados de treprostinilo
US9643911B2 (en) 2015-06-17 2017-05-09 Corsair Pharma, Inc. Treprostinil derivatives and compositions and uses thereof
US9394227B1 (en) 2015-06-17 2016-07-19 Corsair Pharma, Inc. Treprostinil derivatives and compositions and uses thereof
US10898494B2 (en) 2016-05-05 2021-01-26 Liquidia Technologies, Inc. Dry powder treprostinil for the treatment of pulmonary hypertension
US20180153847A1 (en) 2016-09-26 2018-06-07 United Therapeutics Corporation Treprostinil prodrugs
MX2021013329A (es) 2019-04-29 2022-03-17 Insmed Inc Composiciones de polvo seco de los profarmacos de treprostinil y métodos de uso de las mismas.
US11634443B2 (en) 2019-08-23 2023-04-25 United Therapeutics Corporation Treprostinil prodrugs
JP2023523557A (ja) 2020-04-17 2023-06-06 ユナイテッド セラピューティクス コーポレイション 間質性肺疾患の治療における使用のためのトレプロスチニル
CA3180230A1 (en) 2020-06-09 2021-12-16 Hitesh Batra Fumaryl diketopiperidine prodrugs of treprostinil
US11826328B2 (en) 2020-12-14 2023-11-28 United Therapeutics Corporation Stable treprostinil prodrugs

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT947196E (pt) * 1997-03-14 2009-09-24 Toray Industries Preparação de derivado de prostaglandina i de libertação prolongada
US20010006979A1 (en) * 1998-07-08 2001-07-05 Richard Stratton Method for treatment of fibrosis related diseases by the administration of prostacyclin derivatives
EP1420794B1 (en) * 2001-08-31 2017-12-27 Sucampo AG Prostaglandin analogs as chloride channel openers
US7550133B2 (en) * 2002-11-26 2009-06-23 Alexza Pharmaceuticals, Inc. Respiratory drug condensation aerosols and methods of making and using them
CN102697790A (zh) * 2003-05-22 2012-10-03 联合治疗公司 化合物和释放前列环素类似物的方法
US20040265238A1 (en) * 2003-06-27 2004-12-30 Imtiaz Chaudry Inhalable formulations for treating pulmonary hypertension and methods of using same
US20080096915A1 (en) * 2005-01-13 2008-04-24 Greenberg Traurig LLP Compositions for the treatment of metabolic disorders
EP2111863B1 (en) * 2005-10-26 2012-03-28 Asahi Kasei Pharma Corporation Fasudil in combination with bosentan for the treament of pulmonary arterial hypertension
US8318802B2 (en) * 2006-02-03 2012-11-27 Actelion Pharmaceuticals Ltd. Epoprostenol formulation and method of making thereof
KR20090117781A (ko) * 2007-02-09 2009-11-12 유나이티드 세러퓨틱스 코오포레이션 간질성 폐질환 및 천식을 위한 트레프로스티닐 치료법

Also Published As

Publication number Publication date
SG178315A1 (en) 2012-03-29
KR101729800B1 (ko) 2017-04-24
GT201200038A (es) 2015-01-16
BR112012002578A2 (pt) 2016-03-15
SI2461812T1 (sl) 2014-05-30
CA2770066A1 (en) 2011-02-10
JP2013501032A (ja) 2013-01-10
CN102548559A (zh) 2012-07-04
ZA201200790B (en) 2013-05-29
HN2012000297A (es) 2015-05-18
RS53234B (en) 2014-08-29
JP5877787B2 (ja) 2016-03-08
PL2461812T3 (pl) 2014-12-31
US20160175319A1 (en) 2016-06-23
IL217899A0 (en) 2012-03-29
US10086001B2 (en) 2018-10-02
EA023720B1 (ru) 2016-07-29
CL2012000319A1 (es) 2012-09-14
EP2461812B1 (en) 2014-01-01
CY1114983T1 (el) 2016-12-14
AU2010280684B2 (en) 2016-07-28
US20120184622A1 (en) 2012-07-19
CN102548559B (zh) 2013-12-25
AU2010280684A1 (en) 2012-02-23
CA2770066C (en) 2018-10-23
SMT201400057B (it) 2014-07-07
WO2011015630A1 (en) 2011-02-10
HK1165293A1 (en) 2012-10-05
EP2461812A1 (en) 2012-06-13
KR20120056819A (ko) 2012-06-04
PT2461812E (pt) 2014-04-07
BR112012002578B1 (pt) 2021-01-12
ES2451790T3 (es) 2014-03-28
HRP20140277T1 (hr) 2014-04-25
BR112012002578B8 (pt) 2021-05-25
DK2461812T3 (da) 2014-04-07
IL217899B (en) 2018-05-31

Similar Documents

Publication Publication Date Title
EA201200253A1 (ru) Композиция для лечения муковисцидоза
IN2012DN01233A (ru)
TW200722081A (en) New therapeutic combinations for the treatment or prevention of depression
UA98373C2 (ru) Конденсированные гетероциклические производные и их применение как c-met ингибиторов
EA201300892A1 (ru) Новые композиции для лечения муковисцидоза
MX2011007750A (es) Composiciones y metodos para inhibicion de la ruta jak.
EA201200143A1 (ru) Антибактериальная композиция для ротовой полости
TW200806300A (en) New therapeutic combinations for the treatment of depression
IN2012DN00624A (ru)
MX2009010132A (es) Analogos de pirazolopirimidina y su uso como inhibidores de cinasa mtor y cinasa pi3.
GEP20125624B (en) Pyridazine derivatives as smo inhibitors
PE20121617A1 (es) Derivados de oxazina como inhibidores de bace
TW201000473A (en) Benzene or thiophene derivative and use thereof as VAP-1 inhibitor
MX369385B (es) Productos para cicatrizar heridas tisulares.
TW200716091A (en) New therapeutic combinations for the treatment or prevention of psychotic disorders
MX2011013032A (es) Inhibidores de fosfatidilinositol 3-cinasa.
MX2020009397A (es) Composiciones y metodos para inhibicion de la via jak.
EA201390428A1 (ru) Композиции и способы лечения легочной гипертензии
GEP201706656B (en) 2-thiopyrimidinones
TN2010000038A1 (en) Organic compounds
MX2010001243A (es) Composicion anti-inflamatoria.
MX2011008645A (es) Inhibidores de tetrahidrotiazolopiridina de fosfatidilinositol 3 cinasa.
TW200806321A (en) New therapeutic combinations for the treatment or prevention of psychotic disorders
MX2011011618A (es) Agentes terapeuticos 713.
ZA201008160B (en) Compositions for the treatment of hair loss

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ KG MD TJ TM